Cargando…
Digital Therapeutics in Migraine Management: A Novel Treatment Option in the COVID-19 Era
Migraine is a chronic and often lifelong disease that directly affects over one billion people globally. Because access to migraine medical services is limited, only a minority of migraine patients are treated adequately. This situation worsened during the COVID-19 pandemic. Digital therapeutics (DT...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842514/ https://www.ncbi.nlm.nih.gov/pubmed/36660558 http://dx.doi.org/10.2147/JPR.S387548 |
_version_ | 1784870145853751296 |
---|---|
author | Chen, Xingchen Luo, Yujia |
author_facet | Chen, Xingchen Luo, Yujia |
author_sort | Chen, Xingchen |
collection | PubMed |
description | Migraine is a chronic and often lifelong disease that directly affects over one billion people globally. Because access to migraine medical services is limited, only a minority of migraine patients are treated adequately. This situation worsened during the COVID-19 pandemic. Digital therapeutics (DTx) is an emerging therapeutic approach that opens up many new possibilities for remote migraine management. For instance, migraine management tools, online migraine diagnosis, guideline-based treatment options, digitally networked patients, and collecting anonymized information about migraine attacks and course parameters for scientific evaluation. Various applications of DTx in migraine management have been studied in recent years, such as the usefulness of digital migraine self-management tools in diagnosing and tracking migraine attacks, and the efficacy and safety of digital cognitive behavioural therapy. However, the development of DTx is still in its infancy and still faces many obstacles. The primary goal of this study is to review the latest research on DTx in migraine management, identify challenges, and outline future trends. |
format | Online Article Text |
id | pubmed-9842514 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-98425142023-01-18 Digital Therapeutics in Migraine Management: A Novel Treatment Option in the COVID-19 Era Chen, Xingchen Luo, Yujia J Pain Res Review Migraine is a chronic and often lifelong disease that directly affects over one billion people globally. Because access to migraine medical services is limited, only a minority of migraine patients are treated adequately. This situation worsened during the COVID-19 pandemic. Digital therapeutics (DTx) is an emerging therapeutic approach that opens up many new possibilities for remote migraine management. For instance, migraine management tools, online migraine diagnosis, guideline-based treatment options, digitally networked patients, and collecting anonymized information about migraine attacks and course parameters for scientific evaluation. Various applications of DTx in migraine management have been studied in recent years, such as the usefulness of digital migraine self-management tools in diagnosing and tracking migraine attacks, and the efficacy and safety of digital cognitive behavioural therapy. However, the development of DTx is still in its infancy and still faces many obstacles. The primary goal of this study is to review the latest research on DTx in migraine management, identify challenges, and outline future trends. Dove 2023-01-12 /pmc/articles/PMC9842514/ /pubmed/36660558 http://dx.doi.org/10.2147/JPR.S387548 Text en © 2023 Chen and Luo. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Chen, Xingchen Luo, Yujia Digital Therapeutics in Migraine Management: A Novel Treatment Option in the COVID-19 Era |
title | Digital Therapeutics in Migraine Management: A Novel Treatment Option in the COVID-19 Era |
title_full | Digital Therapeutics in Migraine Management: A Novel Treatment Option in the COVID-19 Era |
title_fullStr | Digital Therapeutics in Migraine Management: A Novel Treatment Option in the COVID-19 Era |
title_full_unstemmed | Digital Therapeutics in Migraine Management: A Novel Treatment Option in the COVID-19 Era |
title_short | Digital Therapeutics in Migraine Management: A Novel Treatment Option in the COVID-19 Era |
title_sort | digital therapeutics in migraine management: a novel treatment option in the covid-19 era |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842514/ https://www.ncbi.nlm.nih.gov/pubmed/36660558 http://dx.doi.org/10.2147/JPR.S387548 |
work_keys_str_mv | AT chenxingchen digitaltherapeuticsinmigrainemanagementanoveltreatmentoptioninthecovid19era AT luoyujia digitaltherapeuticsinmigrainemanagementanoveltreatmentoptioninthecovid19era |